Wilson Sonsini Goodrich & Rosati has advised Beren Therapeutics P.B.C. Latham & Watkins has advised Hercules Capital, Inc. Beren Therapeutics P.B.C., a biotechnology company and parent...
Beren Therapeutics Secures $300 Million in Equity, Debt, and Royalty Financing
Royalty Pharma Acquires Royalty Interest in Amgen’s Imdelltra from BeOne Medicines for Up to $950 Million
Gibson Dunn & Crutcher, Dechert and Maiwald have advised Royalty Pharma. Royalty Pharma plc has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for...
RTW Investments Leads $85 Million Equity Offering by Aquestive Therapeutics
Gibson Dunn has advised RTW Investments, LP. , Dechert has advised Aquestive Therapeutics, Inc. and Cooley has advised the underwriters. RTW Investments, LP has acquired common...
RTW Investments Acquires Synthetic Royalty Interest in Anaphylm and Participates in Aquestive Therapeutics’ $85 Million Offering
Gibson Dunn has advised RTW Investments, LP. RTW Investments, LP has acquired a synthetic royalty interest in Anaphylm™ (epinephrine) Sublingual Film from Aquestive Therapeutics, Inc. Additionally,...
US WorldMeds Acquires Adaptimmune’s Cell Therapy Portfolio for $55 Million
Gibson, Dunn & Crutcher LLP has advised US WorldMeds on the transaction, and Ropes & Gray LLP has advised Adaptimmune Therapeutics plc. US WorldMeds has entered...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
Ocumension Therapeutics’ Acquisition of Alcon’s Rights
Gibson, Dunn & Crutcher advised Alcon Inc. on the deal, and Morrison & Foerster advised OcuMension Therapeutics. OcuMension Therapeutics (“OcuMension”), a Hong Kong-listed, China-based ophthalmic pharmaceutical...
Arrowhead Pharmaceuticals’ Financing Agreement with Sixth Street
Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...
Esperion Therapeutics’ Royalty Purchase Agreement with OMERS
Gibson Dunn & Crutcher advised Esperion Therapeutics, Inc. on the deal. Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced that it has entered into a Royalty Purchase Agreement...
XOMA’s Acquisition of Economic Interest in Three Women’s Health Assets
Gibson, Dunn & Crutcher represented XOMA Corporation in the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Daré. XOMA Corporation (NASDAQ: XOMA) announced...
XOMA’s $8 Million Acquisition of DSUVIA
Gibson, Dunn & Crutcher LLP advised XOMA Corporation on the expansion of its commercial royalty and milestone portfolio with the acquisition of an economic interest in...